American Society of Hematology
-
Publisher Of
-
Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.
Blood.
140:594-595.
2022
-
The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Blood Advances.
5:1933-1946.
2021
-
A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.
Blood.
136:5-5.
2020
-
Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.
Blood.
136:1113-1113.
2020
-
Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality.
Blood.
134:518-518.
2019
-
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Blood Advances.
3:3248-3260.
2019
-
CD138− plasma cell myeloma.
Blood.
134:906-906.
2019
-
Development of a Quality of Life Instrument Specific for Cutaneous Lymphoma.
Blood.
118:3158-3158.
2011
-
The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal.
Blood.
118:5429-5438.
2011
-
Molecular basis of LMAN1 in coordinating LMAN1-MCFD2 cargo receptor formation and ER-to-Golgi transport of FV/FVIII.
Blood.
116:5698-5706.
2010
-
EF-hand domains of MCFD2 mediate interactions with both LMAN1 and coagulation factor V or VIII.
Blood.
115:1081-1087.
2010
-
C/Ebpa Gene Mutation and C/Ebpa Promoter Hypermethylation in Acute Myeloid Leukemia with Normal Cytogenetics..
Blood.
114:1570-1570.
2009
-
Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991.
Blood.
112:9-9.
2008
-
Patients Are Willing to Trade off Efficacy, Safety, and Administration Attributes of Chronic Idiopathic Purpura (ITP) Therapy: Results from a Large North American Discrete Choice Study.
Blood.
112:669-669.
2008
-
Predictors of Acute Intracranial Pathology Identified by Computerized Tomography in Children with Sickle Cell Disease..
Blood.
108:3798-3798.
2006
-
The Addition of Fludarabine to a Conventional Busulfan/Melphalan/Anti-Thymocyte Globulin (Flu/Bu/Mel/ATG) Preparative Regimen Increased Engraftment without Additional Toxicity..
Blood.
108:2944-2944.
2006
-
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study..
Blood.
108:2467-2467.
2006
-
Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
Blood.
106:1552-1558.
2005
-
Your Ad here: optimizing adenoviral vector-based vaccines.
Blood.
104:2612-2613.
2004
-
Progress with unrelated cord blood transplants in adults.
Blood.
101:4648-4648.
2003
-
A novel beta-globin mutation, beta Durham-NC [beta 114 Leu-->Pro], produces a dominant thalassemia-like phenotype.
Blood.
83:1109-1116.
1994
-
Tackling T-cell tumors.
Blood.
102:2313-2313.
2003
-
A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia.
Blood.
792-794.
2022
-
Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study.
Blood.
3885-3886.
2022
-
Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes.
Blood.
2570-2571.
2022
-
Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response.
Blood.
3122-3122.
2022
-
Characterizing Frailty in Adults with Sickle Cell Disease Using Frailty Phenotype.
Blood.
5125-5126.
2022
-
Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion.
Blood.
4135-4136.
2022
-
Fever and Neutropenia Management and Infectious Prevention Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study.
Blood.
5037-5038.
2022
-
Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association.
Blood.
9165-9166.
2022
-
Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists.
Blood.
13033-13034.
2022
-
Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes.
Blood.
10845-10846.
2022
-
In Their Own Words: A Qualitative Study of Coping Mechanisms Employed By Patients with Acute Myeloid Leukemia.
Blood.
13267-13268.
2022
-
Infectious Disease Antimicrobial Prophylaxis Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study.
Blood.
10784-10785.
2022
-
Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat.
Blood.
5313-5315.
2022
-
Measuring Physical Activity in Younger and Older Adults with Sickle Cell Disease Using Accelerometers.
Blood.
7995-7996.
2022
-
Normoglycemic Blood Banking with Automated Glucose Feeding.
Blood.
8564-8565.
2022
-
Prevalence of Dependence in Activities of Daily Living in Adults with Sickle Cell Disease and Its Association with Disease Complications.
Blood.
11125-11126.
2022
-
Prevention and Management of Sickle Cell Pain Crises: Lessons Learned from Older Adults with Sickle Cell Disease.
Blood.
8003-8004.
2022
-
Prolymphocytic Progression of Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: A Nationwide Veterans Affairs Retrospective Review.
Blood.
4176-4177.
2022
-
Rare Deleterious TCF3
Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children.
Blood.
990-991.
2022
-
Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407).
Blood.
7946-7947.
2022
-
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies.
Blood.
10357-10359.
2022
-
Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance]).
Blood.
936-939.
2022
-
The Mental Health Burden and Quality of Life Impact of Myelodysplastic Syndromes in Patients and Their Caregivers.
Blood.
8122-8123.
2022
-
The Morphologic Spectrum of Myelokathexis in WHIM Syndrome and Germline CXCR4
Variants: New Insights into Cellular Changes in the Bone Marrow and Peripheral Blood.
Blood.
5487-5489.
2022
-
The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World.
Blood.
13264-13266.
2022
-
The Role of a Multi-Center Tumor Board Discussion in Managing Acute Leukemia in Under-Resourced Settings.
Blood.
8138-8139.
2022
-
Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study.
Blood.
6765-6766.
2022
-
Urinary C-Telopeptide of Type II Collagen As a Marker of Avascular Necrosis in Younger and Older Adults with Sickle Cell Disease.
Blood.
11116-11117.
2022
-
Utilization of Pharmacogenomics in Assessment of Tolerability and Efficacy of BTK Inhibitors.
Blood.
11573-11574.
2022
-
Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-Up from a Single Center.
1827-1827.
2021
-
Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks.
Blood.
9-9.
2021
-
Acute Myeloid Leukemia in Western Kenya: A Snapshot.
Blood.
1223-1223.
2021
-
Bob.1 Blocks a SYK Protein Degradation Pathway in Mice That Develop Chronic Graft Versus Host Disease Manifestations.
Blood.
3815-3815.
2021
-
Chidamide Maintenance Therapy after Induction or Salvage Treatment in Patients with Peripheral T-Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation.
Blood.
2442-2442.
2021
-
Code Status Transitions in Patients with High-Risk Acute Myeloid Leukemia (AML).
Blood.
109-109.
2021
-
Dasatinib Treatment Patterns after Pleural Effusion Among Patients with Chronic Myeloid Leukemia.
Blood.
3607-3607.
2021
-
Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms.
Blood.
2395-2395.
2021
-
Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Blood.
3043-3043.
2021
-
Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study.
Blood.
848-848.
2021
-
Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD).
Blood.
3786-3786.
2021
-
Epidemiologic Evaluation of Clinical Outcomes in Ethnic Minorities with Myelodysplastic Syndromes.
Blood.
4132-4132.
2021
-
Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study.
Blood.
8-8.
2021
-
Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome.
Blood.
421-421.
2021
-
Healthcare Resource Utilization and Costs in US Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Chemotherapy.
Blood.
4039-4039.
2021
-
Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Is Associated with Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood Transplantation.
Blood.
333-333.
2021
-
High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance).
Blood.
221-221.
2021
-
Identifying and Overcoming Barriers in Clinical Trial Enrollment for Veterans with Blood Cancers.
Blood.
1920-1920.
2021
-
Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101.
Blood.
3956-3956.
2021
-
Living Beyond Life Expectancy: Experience with Aging for Older Adults with Sickle Cell Disease.
Blood.
492-492.
2021
-
MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT.
Blood.
2955-2955.
2021
-
National Survey of Pediatric Sickle Cell Providers on Their Contraceptive Practices for Female Patients.
Blood.
1898-1898.
2021
-
Novel Prognostic Markers in Previously Treated Chronic Lymphocytic Leukemia.
Blood.
4688-4688.
2021
-
Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis.
Blood.
1451-1451.
2021
-
Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry.
Blood.
428-428.
2021
-
Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population.
Blood.
4983-4983.
2021
-
Review of Unrelated Donor Cord Blood Transplantation in Children over the Past 3 Decades.
Blood.
2903-2903.
2021
-
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies.
Blood.
3134-3134.
2021
-
Sickle Cell Screening in Children in a Resource Constrained Environment: Diagnosis and Follow up.
Blood.
4068-4068.
2021
-
Symptoms and Impacts Reported By Patients with Acute Myeloid Leukemia (AML) in Remission Post-Stem Cell Transplant.
Blood.
278-278.
2021
-
The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia.
Blood.
4131-4131.
2021
-
The Relationship between Depression, Anxiety, and Clinical Trial Perceptions Among Patients with Hematologic Cancer.
Blood.
1901-1901.
2021
-
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone Acetate in Peripheral T Cell Lymphomas: A Real-World, Retrospective Case Series from China.
Blood.
4563-4563.
2021
-
Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia.
Blood.
4404-4404.
2021
-
What Do Patients Think about Palliative Care? a National Survey of Hematopoietic Stem Cell Transplant Recipients.
Blood.
2968-2968.
2021
-
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study.
Blood.
567-567.
2021
-
Annual Healthcare Resource Utilization and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia.
Blood.
13-14.
2020
-
Barriers and Facilitators of Advance Care Planning for Older Adults with Sickle Cell Disease.
Blood.
58-59.
2020
-
COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy.
Blood.
23-24.
2020
-
Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies.
Blood.
11-11.
2020
-
Decisional Involvement, Information Preferences, and Prognostic Optimism Among Patients with Hematologic Malignancies.
Blood.
42-43.
2020
-
Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia.
Blood.
24-25.
2020
-
Financial Burden Is Associated with Postponing Care and Decreasing Physical and Emotional Quality of Life Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia.
Blood.
45-45.
2020
-
Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis.
Blood.
2-3.
2020
-
Functional Assessment in Younger and Older Adults with Sickle Cell Disease.
Blood.
26-27.
2020
-
Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts.
Blood.
52-52.
2020
-
How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?.
Blood.
52-53.
2020
-
Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML).
Blood.
38-39.
2020
-
Integration of EHR and Cancer Registry Data to Construct a Childhood Cancer Survivorship Cohort to Improve Long-Term Follow-up Care for Leukemia and Lymphoma Survivors.
Blood.
8-8.
2020
-
Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant.
Blood.
24-25.
2020
-
Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML).
Blood.
26-27.
2020
-
Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial.
Blood.
29-30.
2020
-
Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML).
Blood.
44-45.
2020
-
Restoration of Normal Blood Flow in Mouse Models of Sickle Cell Vaso-Occlusion Following Intravenous or Subcutaneous Administration of a Highly Potent E-Selectin Specific Inhibitor.
Blood.
17-17.
2020
-
Systematic Evaluation of Somatic Cis
-Regulatory Mutations in Follicular Lymphoma.
Blood.
26-27.
2020
-
Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition.
Blood.
4-5.
2020
-
The Accuracy of Physical Examination to Diagnose Anemia Among Patients 5 Years of Age or Older: A Systematic Review of the Literature.
Blood.
23-24.
2020
-
Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors.
Blood.
20-20.
2020
-
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM).
Blood.
3157-3157.
2019
-
A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center.
Blood.
3471-3471.
2019
-
Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP.
Blood.
1623-1623.
2019
-
Anaerobic Antibiotics and the Risk of Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Blood.
1992-1992.
2019
-
Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents.
Blood.
2019
-
Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies.
Blood.
384-384.
2019
-
Building a National CML Registry.
Blood.
3440-3440.
2019
-
Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors.
Blood.
4787-4787.
2019
-
Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning.
Blood.
2891-2891.
2019
-
Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency.
Blood.
949-949.
2019
-
Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry.
Blood.
1843-1843.
2019
-
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation.
Blood.
2021-2021.
2019
-
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency.
Blood.
2175-2175.
2019
-
Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation.
Blood.
2210-2210.
2019
-
Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors.
Blood.
4613-4613.
2019
-
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies.
Blood.
502-502.
2019
-
Emergency Department Encounters, Hospitalizations and ED Reliance Among Medicaid Eligible Patients with Sickle Cell Disease in North Carolina.
Blood.
2113-2113.
2019
-
Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease.
Blood.
4521-4521.
2019
-
Financial Incentives to Increase Stool Collection Rates for Microbiome Studies in Adult Bone Marrow Transplant Patients.
Blood.
5775-5775.
2019
-
Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation.
Blood.
1984-1984.
2019
-
Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma.
Blood.
1499-1499.
2019
-
Hydroxyurea Prescription Fills and Adherence, Among Pediatric and Adult Medicaid Eligible Patients with Sickle Cell Disease in North Carolina.
Blood.
3391-3391.
2019
-
Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach.
Blood.
2112-2112.
2019
-
Impact of Capacity Development Program on Outcomes for Pediatric Hematologic Malignancies in Tanzania.
Blood.
4744-4744.
2019
-
Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis.
Blood.
5105-5105.
2019
-
Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease.
Blood.
4433-4433.
2019
-
Mn Porphyrin-Based Redox Active Drugs Improve Anemia and Reduce Organ Damage in a Murine Model of Sickle Cell Disease.
Blood.
2255-2255.
2019
-
No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial.
Blood.
146-146.
2019
-
Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods Study.
Blood.
2215-2215.
2019
-
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Blood.
4453-4453.
2019
-
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia.
Blood.
705-705.
2019
-
Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects.
Blood.
616-616.
2019
-
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma.
Blood.
926-926.
2019
-
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone.
Blood.
3177-3177.
2019
-
Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality.
Blood.
5731-5731.
2019
-
Proteomic Discovery: Elevated Neurogranin Levels in Children with Sickle Cell Disease.
Blood.
2296-2296.
2019
-
Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency.
Blood.
3515-3515.
2019
-
Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma.
Blood.
3492-3492.
2019
-
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Blood.
3145-3145.
2019
-
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma.
Blood.
3165-3165.
2019
-
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
Blood.
1869-1869.
2019
-
Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active.
Blood.
1388-1388.
2019
-
Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma.
Blood.
141-141.
2019
-
Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd.
Blood.
874-874.
2019
-
T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study.
Blood.
142-142.
2019
-
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Blood.
877-877.
2019
-
Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family.
Blood.
3498-3498.
2019
-
Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect® MM Registry.
Blood.
3129-3129.
2019
-
Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia.
Blood.
4730-4730.
2019
-
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
Blood.
1888-1888.
2019
-
2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials.
Blood.
3978-3978.
2018
-
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies.
Blood.
27-27.
2018
-
A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma.
Blood.
3229-3229.
2018
-
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912).
Blood.
2018
-
Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study.
Blood.
1999-1999.
2018
-
Allergic Sensitization Is Associated with Decreased Risk of ED Visits and Hospitalizations for Pain in Sickle Cell Disease.
Blood.
3676-3676.
2018
-
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study.
Blood.
2170-2170.
2018
-
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 (CaMKK2) Expressed in the Host Promotes Lymphoma Cells Growth By Controlling Myeloid Derived Suppressor Cells Expansion.
Blood.
272-272.
2018
-
Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd.
Blood.
599-599.
2018
-
Disparities in Foundation and Federal Support and Development of New Therapeutics for Sickle Cell Disease and Cystic Fibrosis.
Blood.
4687-4687.
2018
-
End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies.
Blood.
829-829.
2018
-
Endothelial Cell-Derived Extracellular Vesicles Mitigate Radiation-Induced Hematopoietic Injury.
Blood.
2581-2581.
2018
-
Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients.
Blood.
5540-5540.
2018
-
Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency.
Blood.
4807-4807.
2018
-
Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry.
Blood.
4736-4736.
2018
-
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202.
Blood.
6-6.
2018
-
Intestinal Enterococcus Is a Major Risk Factor for the Development of Acute Gvhd.
Blood.
358-358.
2018
-
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study.
Blood.
561-561.
2018
-
Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand.
Blood.
2228-2228.
2018
-
Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom.
Blood.
4042-4042.
2018
-
Long-Term Antithrombotic Therapy after Venous Stent Placement.
Blood.
2018
-
Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant.
Blood.
608-608.
2018
-
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Blood.
26-26.
2018
-
Mn Porphyrin-Based Redox Active Drugs As Novel Anti-Adhesive and Anti-Inflammatory Agents Targeting Sickle Red Blood Cell Oxidative Damage In Vivo.
Blood.
270-270.
2018
-
Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival.
Blood.
811-811.
2018
-
Omission of Maintenance in Patients with High-Risk Acute Promyelocytic Leukemia (APL) in the Era of ATRA/Arsenic Consolidation.
Blood.
5192-5192.
2018
-
Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy.
Blood.
2688-2688.
2018
-
Outpatient Healthcare Utilization and Rates of Co-Management Among Medicaid Patients with Sickle Cell Disease in North Carolina.
Blood.
4725-4725.
2018
-
Palliative Care Physicians' Views Toward Hematology and the Care of Patients with Hematologic Diseases: Results of a Nationwide Survey.
Blood.
4783-4783.
2018
-
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey.
Blood.
5843-5843.
2018
-
Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study.
Blood.
2290-2290.
2018
-
Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203.
Blood.
1403-1403.
2018
-
Predictors of Patient-Reported Communication with Their Health Care Team about New Treatment Options for Chronic Lymphocytic Leukemia.
Blood.
5870-5870.
2018
-
Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation.
Blood.
2123-2123.
2018
-
Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
Blood.
155-155.
2018
-
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia.
Blood.
33-33.
2018
-
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma.
Blood.
1993-1993.
2018
-
Sleep Disturbance Among Individuals with Multiple Myeloma: The Interplay between Physical and Psychosocial Symptoms.
Blood.
4830-4830.
2018
-
The Impact of Cumulative Dose of Cytarabine Consolidation on Outcomes in Older Patients with Acute Myeloid Leukemia.
Blood.
2687-2687.
2018
-
Trajectories of Sickle Cell Disease Severity during Transition to Adult Care.
Blood.
318-318.
2018
-
Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry.
Blood.
3232-3232.
2018
-
Treatment Decision Making and Treatment Satisfaction Among Individuals Living with Chronic Myeloid Leukemia.
Blood.
4787-4787.
2018
-
Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States.
Blood.
497-497.
2018
-
Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function.
Blood.
4594-4594.
2018
-
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia.
Blood.
895-895.
2018
-
Use of a Processed Hematopoietic Stem Cell Product (FCRx) in Unmatched Related and Unrelated Donor — Recipient Pairs Is Associated with High Levels of Donor Chimerism and Donor-Specific Tolerance to Kidney Allografts.
Blood.
202-202.
2018
-
hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis.
Blood.
1346-1346.
2018
-
A Comparison of an Individualized and Weight-Based Opioid Protocols for the Treatment of Vaso-Occlusive Episodes in the Emergency Department.
Blood.
3674-3674.
2016
-
A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia (SWOG 1312).
Blood.
1634-1634.
2016
-
A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Blood.
1068-1068.
2016
-
A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML).
Blood.
340-340.
2016
-
A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).
Blood.
211-211.
2016
-
A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas.
Blood.
2991-2991.
2016
-
A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT).
Blood.
505-505.
2016
-
Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning.
Blood.
3395-3395.
2016
-
All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients.
Blood.
669-669.
2016
-
Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS): Clinical Outcomes from a Phase 1 Safety Study.
Blood.
2284-2284.
2016
-
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).
Blood.
221-221.
2016
-
Aptamer Mediated Inhibition of Protein S.
Blood.
4946-4946.
2016
-
Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis.
Blood.
88-88.
2016
-
Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study.
Blood.
249-249.
2016
-
Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies.
Blood.
4002-4002.
2016
-
Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival.
Blood.
1613-1613.
2016
-
Cost-Effectiveness of Blood Transfusions Versus Observation for Silent Cerebral Infarcts from the Silent Cerebral Infarct Trial.
Blood.
3655-3655.
2016
-
Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry.
Blood.
3548-3548.
2016
-
Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial.
Blood.
903-903.
2016
-
EGF Accelerates Hematopoietic Stem Cell Regeneration Following 5-FU Chemotherapy Via G-CSF Receptor Signaling.
Blood.
1490-1490.
2016
-
ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib.
Blood.
3090-3090.
2016
-
ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma.
Blood.
1755-1755.
2016
-
Effect of FXIII Polymorphism on Formation of Heterocellular Aggregates in SCD.
Blood.
3648-3648.
2016
-
Factors Related to the Progression of Sickle Cell Disease Nephropathy.
Blood.
9-9.
2016
-
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat.
Blood.
1166-1166.
2016
-
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
Blood.
1069-1069.
2016
-
Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents.
Blood.
5126-5126.
2016
-
GWAS Meta-Analysis of Glomerular Filtration Rate in Three Cohorts of Sickle Cell Disease Patients and In Vivo Functional Analysis Reveals Potential Nephropathy Candidate Genes.
Blood.
269-269.
2016
-
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry.
Blood.
537-537.
2016
-
Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report.
Blood.
2890-2890.
2016
-
Mechanism of Complement Activation By PF4/ Heparin Complexes.
Blood.
137-137.
2016
-
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes.
Blood.
3734-3734.
2016
-
PCTP (Phosphatidylcholine Transfer Protein) is Regulated By RUNX1 in Platelets/Megakaryocytes and is Associated with Adverse Cardiovascular Events.
Blood.
365-365.
2016
-
Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP.
Blood.
1008-1008.
2016
-
Postoperative Venous Thromboembolism in Children Is Increased in Setting of Cancer or Infection.
Blood.
2391-2391.
2016
-
Prospective Implementation of Multi-Disciplinary Obstetric Team Decreases the Mortality Rate of Pregnant Women with Sickle Cell Disease in Ghana.
Blood.
1017-1017.
2016
-
RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit.
Blood.
3823-3823.
2016
-
Recipient-Derived BAFF and Alloantigen Synergistically Activate B Cells in Murine Chronic Gvhd.
Blood.
498-498.
2016
-
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Blood.
5696-5696.
2016
-
Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML).
Blood.
98-98.
2016
-
Ruxolitinib Used to Treat Hypereosinophilic Syndrome.
Blood.
5500-5500.
2016
-
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).
Blood.
901-901.
2016
-
Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis.
Blood.
645-645.
2016
-
Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival.
Blood.
1793-1793.
2016
-
Simultaneous Measurement of Cerebral Blood Flow and Arterial Transit Time for Sickle Cell Disease.
Blood.
1298-1298.
2016
-
Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease.
Blood.
3651-3651.
2016
-
Surface CD5 Protein Risk Stratifies Chronic Lymphocytic Leukemia.
Blood.
3212-3212.
2016
-
Survival after Relapse Following Tandem Allogeneic Vs. Tandem Autologous Hematopoietic Cell Transplantation (HCT) for Myeloma (MM).
Blood.
833-833.
2016
-
The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial.
Blood.
3824-3824.
2016
-
Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia.
Blood.
2491-2491.
2016
-
Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611).
Blood.
536-536.
2016
-
Transformation in Pre-Treatment Presentations of Gaucher Disease during the First Two Decades of Imiglucerase Enzyme Replacement Therapy: A Report from the International Collaborative Gaucher Group Gaucher Registry.
Blood.
4877-4877.
2016
-
Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry.
Blood.
4489-4489.
2016
-
Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes.
Blood.
1231-1231.
2016
-
Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis.
Blood.
2390-2390.
2016
-
Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML).
Blood.
590-590.
2016
-
Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML).
Blood.
591-591.
2016
-
Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial.
Blood.
1019-1019.
2016
-
Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study.
Blood.
488-488.
2016
-
Von Willebrand Factor to Prevent Postpartum Hemorrhage.
Blood.
1400-1400.
2016
-
A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma..
Blood.
1857-1857.
2015
-
Characterization of Human and Murine Anti-Protamine/Heparin Antibodies.
Blood.
3461-3461.
2015
-
Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions.
Blood.
2089-2089.
2015
-
Diffuse Large B-Cell Lymphoma Cell of Origin Determination from Formalin-Fixed Paraffin-Embedded Tissues.
Blood.
5052-5052.
2015
-
Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60.
Blood.
796-796.
2015
-
Multiple Myeloma Patient Experience with Financial Toxicity: Findings from the Cancer Experience Registry.
Blood.
874-874.
2015
-
Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE).
Blood.
543-543.
2015
-
Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901.
Blood.
2015
-
The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia.
Blood.
3737-3737.
2015
-
Biologic Activities of Protamine/Heparin Antibodies.
Blood.
2784-2784.
2014
-
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403.
Blood.
796-796.
2014
-
Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study.
Blood.
193-193.
2014
-
Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis.
Blood.
2704-2704.
2014
-
Predicting the Temporal Course of Laboratory Abnormality Resolution in Patients with Thrombotic Microangiopathy.
Blood.
4192-4192.
2014
-
Screening for Neurocognitive Dysfunction in an Adult Population with Sickle Cell Disease.
Blood.
2717-2717.
2014
-
A Risk-Prediction Model For Identifying Venous Thromboembolism In Hospitalized Pediatric Patients: A Single Institution Retrospective Case-Control Analysis.
Blood.
2957-2957.
2013
-
Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience.
Blood.
1383-1383.
2013
-
Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study.
Blood.
2777-2777.
2013
-
Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population.
Blood.
5399-5399.
2013
-
Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease.
Blood.
775-775.
2013
-
GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease.
Blood.
776-776.
2013
-
Humoral Immunity Induced By Viral Infection Provides a Major Barrier To Hematopoietic Cell Transplantation.
Blood.
894-894.
2013
-
In Vivo Modeling Of Genetic Mechanisms Associated With Sickle Cell Disease Nephropathy.
Blood.
2224-2224.
2013
-
MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study.
Blood.
1443-1443.
2013
-
Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia.
Blood.
5282-5282.
2013
-
Neutropenia In Glycogen Storage Disease 1b (GSD1b).
Blood.
2265-2265.
2013
-
OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias.
Blood.
2511-2511.
2013
-
Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT).
Blood.
3350-3350.
2013
-
Palliative Care For Patients With Hematologic Malignancies: A Profile Of Patients With Blood Cancers Referred To The Choice Hospice Network.
Blood.
1678-1678.
2013
-
Perceived Discrimination In Health Care Is Associated With Daily Chronic Pain In Sickle Cell Disease.
Blood.
5577-5577.
2013
-
Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.
Blood.
3027-3027.
2013
-
Pleiotrophin Improves Survival Following Radiation-Induced Myelosuppression and Mediates HSC Expansion Via Induction Of Ras Signaling.
Blood.
1205-1205.
2013
-
Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.
Blood.
213-213.
2013
-
Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.
Blood.
641-641.
2013
-
Recruitment Of T Cells and Macrophages To The Eyes In Recipients Of Allogeneic Hematopoietic Stem Cell Transplants Correlate With Inflammatory Cytokine Presence In Ocular Gvhd.
Blood.
2012-2012.
2013
-
Sevuparin Reduces Adhesion Of Both Sickle Red Cells and Leukocytes To Endothelial Cells In Vitro and Inhibits Vaso-Occlusion In Vivo.
Blood.
182-182.
2013
-
Targeting β-arrestin2 Enhances Survival in a Murine Model of Chronic Myeloid Leukemia.
Blood.
857-857.
2013
-
A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1..
Blood.
2466-2466.
2012
-
A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients.
Blood.
3584-3584.
2012
-
Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes.
Blood.
467-467.
2012
-
An Institutional Experience: Correlation Between Absolute Lymphocyte Count and Survival Outcome After Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies.
Blood.
4541-4541.
2012
-
CD38 Variation in Chronic Lymphocytic Leukemia.
Blood.
4576-4576.
2012
-
Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA).
Blood.
129-129.
2012
-
Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000..
Blood.
2203-2203.
2012
-
Describing Adherence to Recommended Preventative Care Behaviors Among Adults with Sickle Cell Disease.
Blood.
2058-2058.
2012
-
Feasibility and Prognostic Value of VO2peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT).
Blood.
4152-4152.
2012
-
Feasibility of Daily and Weekly Symptom and Health-Related Quality of Life (HRQOL) Surveillance in Patients Receiving Hematopoietic Cell Transplantation (HCT).
Blood.
4471-4471.
2012
-
Genetic Loss of Tmprss6 Increases Effective Erythropoiesis in a Mouse Model of β-Thalassemia.
Blood.
482-482.
2012
-
Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia.
Blood.
878-878.
2012
-
Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations.
Blood.
877-877.
2012
-
High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass.
Blood.
3344-3344.
2012
-
ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom.
Blood.
898-898.
2012
-
Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Severe Phenotype Hurler Syndrome: an International Multi-Center Study.
Blood.
1958-1958.
2012
-
No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial.
Blood.
359-359.
2012
-
Novel Techniques for Measurement of Variable Sized PF4/H Complexes..
Blood.
2204-2204.
2012
-
Outcome of Transplantation for Acute Leukemia in Down Syndrome.
Blood.
1991-1991.
2012
-
PF4/H Complexes Induce Germinal Centers in Vivo.
Blood.
269-269.
2012
-
Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State.
Blood.
87-87.
2012
-
Partial Reversal of Dabigatran Effect by a Prothrombin Complex Concentrate in a Model of Thrombin Generation.
Blood.
3420-3420.
2012
-
Peripheral Blood γδ T Cell Response to High-Grade Glioma: Implications for Localized Adoptive Immunotherapy.
Blood.
4114-4114.
2012
-
Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.
Blood.
4935-4935.
2012
-
Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma.
Blood.
1626-1626.
2012
-
Pilot Study of Sorafenib for Myelodysplastic Syndrome.
Blood.
4948-4948.
2012
-
Polycythemia Vera and Chronic Idiopathic Myelofibrosis CD34+ Cells Preferentially Traffic to Splenic Niches.
Blood.
1750-1750.
2012
-
Proteomic Analysis of ERK1/2-Mediated Human Sickle Red Blood Cell Membrane Protein Phosphorylation..
Blood.
2120-2120.
2012
-
Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol.
Blood.
738-738.
2012
-
Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation.
Blood.
462-462.
2012
-
The Metabolic Signature of CLL: Enhanced Glucose Metabolism in A Subset of High-Risk CLL Patients.
Blood.
1785-1785.
2012
-
Therapeutic Benefit of Small Molecule Inhibitors of MEK/ERK in Reducing Sickle Red Cell Adhesion and Vaso-Occlusion in Vivo.
Blood.
376-376.
2012
-
Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD).
Blood.
1004-1004.
2012
-
Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma.
Blood.
1622-1622.
2012
-
Using High-Throughput Sequencing of Red Blood Cells and Platelets to Identify Micrornas Associated with Hematopoiesis..
Blood.
2326-2326.
2012
-
A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,.
Blood.
3757-3757.
2011
-
Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy.
Blood.
2664-2664.
2011
-
Sickle Red Blood Cell Induced Adhesion of Neutrophils to Endothelial Cells and Biologic Correlates of Leukocyte Activation.
Blood.
1055-1055.
2011
-
Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML.
Blood.
35-35.
2010
-
Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up.
Blood.
206-206.
2010
-
Hydroxyurea Induces Genome-Wide Epigenetic Changes In Sickle Cell Disease.
Blood.
2670-2670.
2010
-
Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study..
Blood.
1047-1047.
2009
-
Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia..
Blood.
2562-2562.
2009
-
Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy..
Blood.
2076-2076.
2009
-
Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML)..
Blood.
2081-2081.
2009
-
Polymorphisms in TNFα Are Associated with Cerebrovascular Events in Sickle Cell Disease..
Blood.
1540-1540.
2009
-
Systemic Administration of Pleiotrophin Induces Hematopoietic Stem Cell Regeneration In Vivo..
Blood.
1498-1498.
2009
-
The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis..
Blood.
802-802.
2009
-
A Genomic Strategy To Refine Prognosis and Predict Response to Therapy in Chronic Lymphocytic Leukemia..
Blood.
3096-3096.
2007
-
Allogeneic Committed Hematopoietic Progenitors Are Protective Against Radiation..
Blood.
4871-4871.
2007
-
Analysis of the Cellular Components of the Graft and Clinical Characteristics of 159 Children with Lysosomal and Peroxisomal Disorders (LSD) Undergoing Unrelated Umbilical Cord Blood Transplantation at a Single Center..
Blood.
336-336.
2007
-
Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia..
Blood.
3081-3081.
2007
-
Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro..
Blood.
3129-3129.
2007
-
Dynamic In Vivo Imaging Reveals That Leukemia-Induced Changes in the Bone Marrow Microenvironment Alter Mechanisms of Metastasis..
Blood.
2805-2805.
2007
-
Efficacy of Hydroxyurea To Prevent Organ Damage in Young Children with Sickle Cell Anemia..
Blood.
3386-3386.
2007
-
Functional and Numerical T Cell Abnormalities in Chronic Lymphocytic Leukemia..
Blood.
3085-3085.
2007
-
Gene Expression Profiles for Prognosis in MGUS, Coupled with Signatures of Oncogenic Pathway Deregulation Provide a Novel Approach for Selection of Molecular Targets in Multiple Myeloma..
Blood.
655-655.
2007
-
Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia..
Blood.
3084-3084.
2007
-
Monoclonal B Cell Lymphocytosis as a Marker of Inherited Predisposition to Chronic Lymphocytic Leukemia..
Blood.
3090-3090.
2007
-
Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432)..
Blood.
440-440.
2007
-
Post Thaw Colony Forming Units (CFU) Is a Strong Independent Predictor of Engraftment after Unrelated Donor Umbilical Cord Blood Transplantation (UCBT)..
Blood.
3282-3282.
2007
-
Post Transplant Autoimmune Hemolytic Anemia and Other Cytopenias Are Increased in Very Young Babies after Unrelated Donor Umbilical Cord Blood Transplantation..
Blood.
1054-1054.
2007
-
Prediction of Heparin Induced Thrombocytopenia: Validation of an Experience-Based Computer Model..
Blood.
3226-3226.
2007
-
Predictors of In-Hospital Mortality and Charges in Sickle Cell Disease: Results from the California Discharge Databases 1998–2005..
Blood.
432-432.
2007
-
Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody..
Blood.
3245-3245.
2007
-
Prolongation of QTc Intervals and Risk of Sudden Death among Patients with Sickle Cell Diseases..
Blood.
2249-2249.
2007
-
Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation for Children with Hurler’s Syndrome. An Eurocord-Duke University Collaborative Study..
Blood.
5076-5076.
2007
-
The Effects of Chronic Opiates Pain Therapy in Sickle Cell Anemia..
Blood.
3404-3404.
2007
-
The Identification and Genomic Analysis of microRNAs in Human Erythrocytes in Sickle Cell Diseases..
Blood.
3400-3400.
2007
-
Treatment of Established Graft-Versus-Host Disease by PG490-88..
Blood.
3243-3243.
2007
-
Use of Mesenchymal Stem Cells To Treat Pediatric Patients with Severe (Grade III–IV) Acute Graft Versus Host Disease Refractory to Steroid and Other Agents on a Compassionate Use Basis..
Blood.
2971-2971.
2007
-
A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS..
Blood.
2669-2669.
2006
-
Acute Graft Versus Host Disease (GVHD) Is Increased in Patients Receiving Cyclosporine/Cellcept as Frontline Prophylaxis Against GVHD in Pediatric Patients Undergoing Allogeneic Stem Cell Transplantation..
Blood.
2896-2896.
2006
-
Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival..
Blood.
5399-5399.
2006
-
Antiproliferative Activity of ELACYT™ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells..
Blood.
1991-1991.
2006
-
Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S..
Blood.
3311-3311.
2006
-
Dosing of Post-Thaw Colony Forming Units (CFU) and CD34 Cells Predict Engraftment and Survival in Recipients of Banked Unrelated Donor Umbilical Cord Blood (UCB) for Allogeneic Transplantation..
Blood.
3197-3197.
2006
-
Evidence for an Adaptive Immune Barrier after in Utero Hematopoietic Cell Transplantation..
Blood.
3179-3179.
2006
-
Gene Expression Patterns Identify Patients with Non-Small Cell Lung Cancer (NSCLC) and Ovarian Cancer Who Are at Increased Risk for Venous Thromboembolism (VTE)..
Blood.
1470-1470.
2006
-
Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909..
Blood.
2737-2737.
2006
-
In Vivo Radiaprotective Effects of Growth Hormone..
Blood.
5158-5158.
2006
-
Melphalan Containing Cytoreduction Results in a Good Overall Survival (OS) in Pediatric Patients with Relapse or Refractory AML Undergoing Unrelated Umbilical Cord Blood Transplantation (UCBT)..
Blood.
3150-3150.
2006
-
Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT..
Blood.
2860-2860.
2006
-
Preliminary Results of a Pilot Trial of Unrelated Umbilical Cord Blood Transplantation (UCBT) Augmented with Cytokine-Primed Aldehyde Dehydrogenase-Bright (ALDHbr) Cells..
Blood.
3641-3641.
2006
-
Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study..
Blood.
219-219.
2006
-
Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study..
Blood.
218-218.
2006
-
Testicular Relapse in Lesser, Standard, and High Risk Patients Treated with Frontline Therapy for Childhood ALL. Pediatric Oncology Group Protocols 9201, 9405, 9605, and 9406..
Blood.
1863-1863.
2006
-
Tissue Factor Is Absent from Sites of Cutaneous Wounds: Implications for Bleeding in Hemophilia..
Blood.
1803-1803.
2006
-
Updated Cost-Effectiveness Analysis of First-Line Imatinib Compared to Interferon-α in Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Chronic Phase Using 60-Month Data from IRIS..
Blood.
3312-3312.
2006
-
Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Novel Genetic Subtypes..
Blood.
2090-2090.
2006
-
Inhibition of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-ALL after Blocking Remote 3′-BCL11B Enhancer Sequences with Matching DNA Oligos Reveals Coregulation by PU.1 and HMGA1..
Blood.
2212-2212.
2006
-
Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8..
Blood.
186-186.
2005
-
Cobalamins and Cobinamides Inhibit Nitric Oxide Synthase Enzymatic Activity..
Blood.
2225-2225.
2005
-
Combination of Daunorubicin and Cytarabine Chemotherapy with Gemtuzumab Ozogamicin as Initial Therapy for Elderly Patients with Previously Untreated Acute Myeloid Leukemia..
Blood.
4636-4636.
2005
-
Corticosteroids and Increased Risk of Readmission after Acute Chest Syndrome..
Blood.
2329-2329.
2005
-
Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors..
Blood.
2036-2036.
2005
-
Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia..
Blood.
4623-4623.
2005
-
Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report..
Blood.
2046-2046.
2005
-
Transplant Outcomes and Stabilization of Neurological Function in Young Children with MPS III (Sanfilippo Syndrome) after Unrelated Donor Umbilical Cord Blood Transplantation..
Blood.
2050-2050.
2005
-
Unique Reversible but Serious Adverse Events in Very Young Infants Undergoing Unrelated Donor Umbilical Cord Blood Transplantation for Non-Malignant Conditions: Increased Autoimmune Cytopenias and Hypertrophic Cardiomyopathy..
Blood.
5456-5456.
2005
-
Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?..
Blood.
860-860.
2004
-
Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9..
Blood.
2824-2824.
2004
-
CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study..
Blood.
810-810.
2004
-
COAT Platelet Formation Is P2Y12-Dependent..
Blood.
1569-1569.
2004
-
Campath-1H May Have Activity in the Treatment of Multiple Myeloma..
Blood.
4931-4931.
2004
-
Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection..
Blood.
1091-1091.
2004
-
Cord Blood Transplantation for Lysosomal Storage Diseases Demonstrates the Potential of Cord Blood Cells for Future Cellular Therapies..
Blood.
3602-3602.
2004
-
Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings..
Blood.
350-350.
2004
-
Dendritic and T Cell Subsets Correlate with the Development and Site of Acute GVHD Following Unrelated Cord Blood Transplantation. A Multivariate Analysis of Host, Graft, and Day+50 Immune Profile..
Blood.
981-981.
2004
-
Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL)..
Blood.
913-913.
2004
-
Effects of Pre-Analytical Variables on the Anti-FXa Chromogenic Assay when Monitoring Unfractionated Heparin and Low Molecular Weight Heparin Anticoagulation..
Blood.
4064-4064.
2004
-
Effects of Single Nucleotide Polymorphisms of the β2 Adrenergic Receptor and of Adenylate Cyclase on Sickle Red Cell Adhesion to Laminin..
Blood.
3565-3565.
2004
-
Epinephrine-Induced Sickle Red Cell Adhesion and Vaso-Occlusion In Vivo Is Inhibited by the β-Adrenoceptor Blocker Propranolol..
Blood.
364-364.
2004
-
Establishment of the NMDP Cord Blood Banking Network..
Blood.
5190-5190.
2004
-
First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study..
Blood.
2210-2210.
2004
-
Genetic Polymorphisms Associated with Risk for Pulmonary Hypertension and Proteinuria in Sickle Cell Disease..
Blood.
1668-1668.
2004
-
Hematopoietic Cell Transplantation for Sickle Cell Disease: Updated Results of the Multicenter Trial..
Blood.
104-104.
2004
-
High Expression of Granzymes and Perforin along with Increased T cell Cycling In Vivo Predicts the Development of Opportunistic Infections (OI) Following Unrelated Cord Blood Transplantation (UCBT)..
Blood.
2238-2238.
2004
-
Hypoxic Vasodilation by Red Blood Cells and Impairment in Vascular Disorders..
Blood.
1585-1585.
2004
-
Immunophenotype and Analysis of Allo-Reactivity of Umbilical Cord Blood (UCB)-Derived T-Cells Following Ex-Vivo Expansion..
Blood.
403-403.
2004
-
Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report..
Blood.
895-895.
2004
-
Multimodal Dose Dense Therapy for Mantle Cell Lymphoma..
Blood.
1163-1163.
2004
-
Point of Care Monitoring of the International Normalized Ratio in Patients with Antiphospholipid Antibodies..
Blood.
1855-1855.
2004
-
Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study..
Blood.
855-855.
2004
-
Protein Kinases Associated with Activation of Sickle Red Blood Cell Adhesion..
Blood.
3567-3567.
2004
-
Pulmonary Hypertension in SS, SC and Sβ Thalassemia: Prevalence, Associated Clinical Syndromes, and Mortality..
Blood.
1663-1663.
2004
-
Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension..
Blood.
1583-1583.
2004
-
Risk Factors for Intracranial Hemorrhage in Children with Sickle Cell Anemia..
Blood.
1657-1657.
2004
-
Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan..
Blood.
2500-2500.
2004
-
Specialized Bone Marrow Endothelium Defines Microdomains for Tumor and Stem Cell Engraftment..
Blood.
663-663.
2004
-
The Impact of Anemia on Mortality, Cognition and Function in a Racially Diverse Community-Dwelling Elderly Population..
Blood.
1627-1627.
2004
-
Thrombocytopenia Is More Common and Nadir Occurs Earlier with Unfractionated Heparin Than with Low Molecular Weight Heparin - Results from the Prospective Catch Registry..
Blood.
2197-2197.
2004
-
Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia..
Blood.
89-89.
2004